[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"updates-archive-2025-12-18-7":3},{"date":4,"filings":5,"has_more":404,"limit":405,"page":406,"total_count":407},"2025-12-18",[6,14,18,26,33,40,44,50,54,60,64,71,78,85,90,94,101,105,112,119,126,133,140,144,150,155,159,166,173,176,181,188,195,202,209,216,223,227,234,241,248,252,259,263,269,276,283,287,294,301,308,312,319,326,330,337,342,346,353,359,366,370,377,380,387,393,397],{"company_name":7,"filing_date":8,"filing_source":9,"headline":10,"id":11,"stock_code":12,"summary_text":13},"Ramco Industries Limited","2025-12-18T11:10:04.261000","NSE","Monthly Report on Re-lodgement of Transfer Requests of Physical Shares - November 2025","6943940a33cbfe5de7221204","RAMCOIND","• Company reports NIL transfer requests received for physical shares during November 2025\n• No requests were processed, approved, or rejected during the month\n• Report submitted in compliance with SEBI Circular No. SEBI\u002FHO\u002FMIRSD\u002FMIRSD-PoD\u002FP\u002FCIR\u002F2025\u002F97\n• Filing dated December 18, 2025\n• Document signed by S. Balamurugasundaram, Company Secretary and Legal Head",{"company_name":7,"filing_date":8,"filing_source":9,"headline":15,"id":16,"stock_code":12,"summary_text":17},"NIL Transfer Requests of Physical Shares for November 2025","6943940b1cc49bc09be03dea","• Company reported zero (NIL) transfer requests of physical shares for November 2025\n• Report submitted in compliance with SEBI Circular No. SEBI\u002FHO\u002FMIRSD\u002FMIRSD-PoD\u002FP\u002FCIR\u002F2025\u002F97 dated July 2, 2025\n• No requests were received, processed, approved, or rejected during the month\n• Filing submitted to both National Stock Exchange (RAMCOIND EQ) and BSE Limited (532369)\n• Document signed by S. Balamurugasundaram, Company Secretary and Legal Head",{"company_name":19,"filing_date":20,"filing_source":21,"headline":22,"id":23,"stock_code":24,"summary_text":25},"Alembic Pharmaceuticals Ltd","2025-12-18T11:05:05.149000","BSE","Alembic Pharmaceuticals Receives USFDA Final Approval for Travoprost Ophthalmic Solution","694393b43418e54cdf8e988a","APLLTD","• Company has received final USFDA approval for Travoprost Ophthalmic Solution USP, 0.004%\n• The product is indicated for reducing intraocular pressure in patients with open-angle glaucoma or ocular hypertension\n• This approval expands Alembic's portfolio in the ophthalmology segment\n• The approval represents a regulatory milestone that will contribute to the company's US market presence",{"company_name":27,"filing_date":28,"filing_source":21,"headline":29,"id":30,"stock_code":31,"summary_text":32},"Ceat Ltd","2025-12-18T11:05:04.923000","CEAT Renames Netherlands Subsidiary to Broaden European Market Focus","6943931733cbfe5de72211f7","500878","• CEAT Limited has changed the name of its wholly owned Netherlands subsidiary from \"CEAT SPECIALTY TYRES B.V.\" to \"CEAT TYRES B.V.\"\n• The name change suggests a strategic shift from specialty focus to a broader tire portfolio in the European market\n• This rebranding likely indicates CEAT's plans to expand its product range and market presence in Europe\n• The change may support CEAT's global growth strategy by removing product limitations implied in the previous name",{"company_name":34,"filing_date":35,"filing_source":21,"headline":36,"id":37,"stock_code":38,"summary_text":39},"Exicom Tele-Systems Ltd","2025-12-18T11:05:04.891000","Exicom Launches Integrated EV Charging Rollout Solution \"Exicom One\"","6943935233cbfe5de72211fd","EXICOM","• Exicom One is a turnkey, integrated solution combining hardware, software, and managed services for EV charging infrastructure deployment\n• The solution targets Charge Point Operators (CPOs), EV manufacturers, and fleet operators looking to scale their charging networks\n• Covers the entire process from site surveys and electrical setup to software integration, operations, and maintenance\n• Recently partnered with a leading EV manufacturer to deploy high-power charging stations along highway corridors\n• Builds on Exicom's existing technologies like AI-based predictive maintenance platform (Harmony Connect)\n• Designed to integrate future technologies including renewable energy systems and Vehicle-to-Grid applications",{"company_name":34,"filing_date":35,"filing_source":21,"headline":41,"id":42,"stock_code":38,"summary_text":43},"Exicom Launches Integrated EV Charging Solution to Accelerate Infrastructure Deployment","694393541cc49bc09be03de2","• Introduced \"Exicom One,\" a turnkey solution that integrates hardware, software, and managed services for EV charging infrastructure deployment\n• Solution targets Charge Point Operators (CPOs), EV manufacturers, and fleet operators looking to scale charging networks efficiently\n• Provides end-to-end services from site surveys and electrical setup to software integration, operations, and maintenance\n• Recently partnered with a leading EV manufacturer to deploy high-power charging stations along highway corridors\n• Builds on Exicom's existing AI-based predictive maintenance platform and mobile charging initiatives",{"company_name":45,"filing_date":46,"filing_source":21,"headline":47,"id":48,"stock_code":12,"summary_text":49},"Ramco Industries Ltd","2025-12-18T11:05:04.830000","Re-lodgement of Transfer Requests of Physical Shares","69439335ca5c132761218022","• Company reported NIL transfer requests of physical shares for November 2025\n• Report submitted in compliance with SEBI Circular No. SEBI\u002FHO\u002FMIRSD\u002FMIRSD-PoD\u002FP\u002FCIR\u002F2025\u002F97 dated July 2, 2025\n• No requests were received, processed, approved, or rejected during the month\n• Filing dated December 18, 2025\n• Submitted to both National Stock Exchange (RAMCOIND EQ) and BSE Limited (532369)",{"company_name":45,"filing_date":46,"filing_source":21,"headline":51,"id":52,"stock_code":12,"summary_text":53},"Re-lodgement of Transfer Requests of Physical Shares - November 2025","694393353418e54cdf8e9885","• Company reported NIL transfer requests of physical shares for November 2025\n• Report submitted in compliance with SEBI Circular No. SEBI\u002FHO\u002FMIRSD\u002FMIRSD-PoD\u002FP\u002FCIR\u002F2025\u002F97 dated July 2, 2025\n• No requests were received, processed, approved, or rejected during the month\n• Filed by S. Balamurugasundaram, Company Secretary and Legal Head\n• Submitted to both National Stock Exchange (RAMCOIND EQ) and BSE Limited (532369)",{"company_name":55,"filing_date":56,"filing_source":9,"headline":57,"id":58,"stock_code":24,"summary_text":59},"Alembic Pharmaceuticals Limited","2025-12-18T11:05:04.351000","USFDA Final Approval for Travoprost Ophthalmic Solution","694392f81cc49bc09be03ddd","• Alembic has received final USFDA approval for Travoprost Ophthalmic Solution USP, 0.004%\n• The product is indicated for reducing intraocular pressure in patients with glaucoma\n• This approval expands Alembic's portfolio of FDA-approved ophthalmic medications\n• Represents a strategic advancement in the company's specialty pharmaceutical offerings\n• Positions Alembic to enter the growing ophthalmic treatment market",{"company_name":55,"filing_date":56,"filing_source":9,"headline":61,"id":62,"stock_code":24,"summary_text":63},"USFDA Final Approval for Travoprost Ophthalmic Solution USP, 0.004%","694392f83418e54cdf8e9881","• Alembic has received final USFDA approval for Travoprost Ophthalmic Solution USP, 0.004% (Ionic Buffered Solution)\n• This medication is indicated for reducing intraocular pressure in patients with glaucoma\n• The approval expands Alembic's portfolio of FDA-approved ophthalmic products\n• This regulatory milestone supports the company's growth strategy in the US pharmaceutical market\n• The approval enables Alembic to manufacture and market this treatment in the United States",{"company_name":65,"filing_date":66,"filing_source":9,"headline":67,"id":68,"stock_code":69,"summary_text":70},"Max Healthcare Institute Limited","2025-12-18T11:05:04.324000","Max Healthcare to Acquire Yerawada Properties for ₹200 Crore, Plans 450-Bed Hospital in Pune","694392a0a471cc3842221113","MAXHEALTH","• Max Healthcare will acquire 100% equity stake in Yerawada Properties Private Limited (YPPL) in a phased manner over ~4 years\n• Initial acquisition includes 100% of Class A equity shares (100% voting rights, ~50.22% economic interest)\n• Total investment of ₹1,020 Crore for acquisition, construction, equipment, and other costs\n• The land parcel (1.68 acres) is located in Yerawada, a prime central location in Pune\n• Strategic expansion into Maharashtra market to meet growing healthcare demand in Pune\n• Will add ~450 beds to Max Healthcare's current ~5,200-bed network\n• Project to be financed through mix of internal accruals and term loans",{"company_name":72,"filing_date":73,"filing_source":21,"headline":74,"id":75,"stock_code":76,"summary_text":77},"Nelco Ltd","2025-12-18T11:00:05.119000","Trading Window Closure for Q3 FY2026 Financial Results","694391eaca5c132761218013","504112","• Trading window for Nelco securities will be closed from December 25, 2025\n• Closure period extends until 48 hours after Q3 FY2026 results are declared\n• Closure applies to all designated persons as per Tata Code of Conduct for Prevention of Insider Trading\n• Notification is in compliance with SEBI Insider Trading Regulations\n• No insider transactions (buy\u002Fsell) are reported in this filing",{"company_name":79,"filing_date":80,"filing_source":21,"headline":81,"id":82,"stock_code":83,"summary_text":84},"Tainwala Chemicals and Plastics (India) Ltd","2025-12-18T11:00:04.959000","Company Responds to Stock Exchanges Regarding Unusual Price Movement","694391caa471cc3842221110","TAINWALCHM","• Tainwala responded to inquiries from BSE and NSE dated December 17, 2025, about significant movement in the company's stock price\n• Company confirmed all required disclosures have been made to stock exchanges\n• No hidden or undisclosed information exists that could affect price\u002Fvolume behavior\n• Price and volume fluctuations are attributed solely to market behavior, not company actions\n• Company explicitly stated it has no role in the recent stock price movements",{"company_name":34,"filing_date":86,"filing_source":21,"headline":87,"id":88,"stock_code":38,"summary_text":89},"2025-12-18T11:00:04.862000","Exicom Launches \"Exicom One\" - End-to-End EV Charging Solution","694391d23418e54cdf8e9879","• Exicom has successfully launched \"Exicom One\" on December 18, 2025\n• Product is a turnkey, integrated EV charging solution for the domestic market\n• Designed for charge point operators (CPOs), EV manufacturers, and fleet operators\n• Enables seamless deployment, operation, and management of EV charging infrastructure\n• Part of the company's strategic expansion of its EV Charger Business",{"company_name":34,"filing_date":86,"filing_source":21,"headline":91,"id":92,"stock_code":38,"summary_text":93},"Exicom Launches Integrated EV Charging Solution \"Exicom One\"","694391d2ca5c132761218011","• Exicom has successfully launched \"Exicom One\" on December 18, 2025\n• Product is a turnkey, integrated EV charging solution for the domestic market\n• Designed as an end-to-end EV charging deployment and operations solution\n• Targets charge point operators (CPOs), EV manufacturers, and fleet operators\n• Aims to enable seamless deployment, operation, and management of EV charging infrastructure",{"company_name":95,"filing_date":96,"filing_source":9,"headline":97,"id":98,"stock_code":99,"summary_text":100},"NELCO Limited","2025-12-18T11:00:04.693000","Trading Window Closure Announced for Q3 FY2026 Financial Results","694391b2ca5c13276121800c","NELCO","• Trading window for Nelco securities will be closed from December 25, 2025\n• Closure period extends until 48 hours after Q3 financial results are declared\n• Closure applies to all designated persons as per Tata Code of Conduct for Prevention of Insider Trading\n• Measure complies with SEBI (Prohibition of Insider Trading) Regulations, 2015\n• Notice signed by Ritesh N Kamdar, Company Secretary (ACS 20154)",{"company_name":95,"filing_date":96,"filing_source":9,"headline":102,"id":103,"stock_code":99,"summary_text":104},"Trading Window Closure Announced Ahead of Q3 FY2026 Results","694391b23418e54cdf8e9875","• Trading window for Nelco securities will be closed from December 25, 2025\n• Closure period extends until 48 hours after Q3 financial results are declared\n• Closure follows Tata Code of Conduct for Prevention of Insider Trading\n• Notification signed by Ritesh N Kamdar, Company Secretary\n• No insider trading activity (buy\u002Fsell) reported in this notification",{"company_name":106,"filing_date":107,"filing_source":9,"headline":108,"id":109,"stock_code":110,"summary_text":111},"Indian Metals & Ferro Alloys Limited","2025-12-18T10:55:04.571000","Loss of Share Certificates Reported","6943907d33cbfe5de72211de","IMFA","• Shareholder SHASHI JHA JT. RAJENDRA KUMAR JHA has reported loss of share certificates\n• Two certificates affected: Certificate #33182 (3 shares) and Certificate #70890 (6 shares)\n• Total of 9 shares reported lost under Folio Number 27959\n• Company has complied with SEBI Regulation 39 regarding loss of share certificates\n• Filing classified as \"Intimation of Loss of Share Certificate\"\n• Date of receipt of intimation: December 18, 2025",{"company_name":113,"filing_date":114,"filing_source":9,"headline":115,"id":116,"stock_code":117,"summary_text":118},"Dolphin Offshore Enterprises (India) Limited","2025-12-18T10:55:04.438000","Company Clarifies No Undisclosed Information Behind Recent Stock Price Movement","694390661cc49bc09be03dc8","DOLPHIN","• Responding to NSE query dated December 17, 2025 regarding unusual price movement\n• Company confirms all material and price-sensitive information has been disclosed within stipulated timeframes\n• No additional information exists that requires disclosure to the stock exchange\n• Management attributes share price fluctuations to being \"purely market driven\"\n• Company reaffirms compliance with Regulation 30 of SEBI Listing Obligations",{"company_name":120,"filing_date":121,"filing_source":21,"headline":122,"id":123,"stock_code":124,"summary_text":125},"Great Eastern Shipping Company Ltd","2025-12-18T10:55:04.156000","G E Shipping Contracts to Sell Kamsarmax Dry Bulk Carrier \"Jag Aarati\"","69439087a83e03833de03d0e","500620","• Company has contracted to sell its 2011-built Kamsarmax Dry Bulk Carrier vessel (80,324 dwt) to an unaffiliated buyer\n• Vessel delivery scheduled for Q4 FY26\n• Current fleet includes 40 vessels: 26 tankers and 14 dry bulk carriers totaling 3.32 million dwt\n• Company has also contracted to sell one Suezmax crude tanker (expected completion in Q3 FY26)\n• Additionally, contracted to purchase one secondhand Ultramax dry bulk carrier (expected completion in Q4 FY26)",{"company_name":127,"filing_date":128,"filing_source":9,"headline":129,"id":130,"stock_code":131,"summary_text":132},"Tembo Global Industries Limited","2025-12-18T10:50:05.062000","Tembo Global Industries Allots 12 Lakh Warrants to Promoters in ₹59.04 Crore Preferential Issue","69438fb4ca5c132761218000","TEMBO","• Company allotted 12,00,000 warrants at ₹492 per warrant to promoter category investors\n• Initial payment of ₹14.76 crore received (25% of total issue price at ₹123 per warrant)\n• Total issue size upon full conversion will be ₹59.04 crore\n• Each warrant convertible into one equity share within 18 months\n• Three promoter allottees: Fatema Shabbir Kachwala (6,00,000 warrants), Piyush Jashbhai Patel (5,00,000 warrants), and Sanjay Patel Holdings Private Limited (1,00,000 warrants)\n• Warrants will be subject to lock-in period as per SEBI regulations\n• Balance 75% (₹369 per warrant) to be paid upon exercise of conversion option",{"company_name":134,"filing_date":135,"filing_source":9,"headline":136,"id":137,"stock_code":138,"summary_text":139},"Shriram Finance Limited","2025-12-18T10:50:04.614000","Shriram Finance Responds to Media Reports About Potential MUFG Investment","69438f5c33cbfe5de72211d5","SHRIRAMFIN","• Company addresses news article claiming Japan's MUFG plans to invest $5 billion for 20% stake\n• Confirms no binding agreement has been executed with any investor at this stage\n• Board meeting scheduled for December 19, 2025 to consider proposals for raising funds\n• Trading window closed from December 17, 2025 for all designated persons\n• Company states there is no material impact from the media report",{"company_name":134,"filing_date":135,"filing_source":9,"headline":141,"id":142,"stock_code":138,"summary_text":143},"Company Responds to Media Rumors About $5 Billion MUFG Investment","69438f5c1cc49bc09be03dc2","• Shriram Finance clarifies it has no binding agreement with any investor, including Japan's MUFG\n• Company confirms board meeting scheduled for December 19, 2025 to consider fund-raising proposals\n• Trading window closed from December 17, 2025 for designated persons\n• Company states there is no material impact from the media speculation\n• No disclosure required during pre-board meeting period per SEBI regulations",{"company_name":145,"filing_date":146,"filing_source":21,"headline":147,"id":148,"stock_code":138,"summary_text":149},"Shriram Finance Ltd","2025-12-18T10:45:05.050000","Shriram Finance Clarifies Media Reports About Potential MUFG Investment","69438f051cc49bc09be03dbe","• Company responds to news article claiming \"Japan's MUFG to invest up to $5 billion in Shriram Finance for 20% stake\"\n• Confirms board meeting scheduled for December 19, 2025 to consider fund-raising proposals\n• States no binding agreement has been executed with any investor at this stage\n• Trading window closed from December 17, 2025 for designated persons\n• Company cites SEBI circular that exempts them from confirming\u002Fdenying market rumors during pre-board meeting period",{"company_name":127,"filing_date":151,"filing_source":9,"headline":152,"id":153,"stock_code":131,"summary_text":154},"2025-12-18T10:45:04.578000","Tembo Global Industries Allots 12,00,000 Convertible Warrants to Promoters for Rs. 59.04 Crore","69438e4bed00186c83217f28","• Company allotted 12,00,000 warrants at Rs. 492 per warrant on preferential basis\n• Total issue size of Rs. 59.04 crore with initial 25% payment (Rs. 14.76 crore) received\n• Warrants convertible into equity shares within 18 months at Rs. 369 per warrant (remaining 75%)\n• All allottees are from Promoter category, including Fatema Shabbir Kachwala (6,00,000 warrants), Piyush Jashbhai Patel (5,00,000 warrants), and Sanjay Patel Holdings Private Limited (1,00,000 warrants)\n• Warrants will be subject to lock-in period as per SEBI regulations",{"company_name":127,"filing_date":151,"filing_source":9,"headline":156,"id":157,"stock_code":131,"summary_text":158},"Allotment of 12,00,000 Convertible Warrants to Promoters at Rs. 492 per Warrant","69438e4f33cbfe5de72211ce","• Company allotted 12,00,000 warrants at Rs. 492 per warrant on preferential basis to promoters\n• Total issue size: Rs. 59.04 crores, with 25% upfront payment (Rs. 14.76 crores) already received\n• Each warrant convertible into one equity share within 18 months\n• Three promoter allottees: Fatema Shabbir Kachwala (6,00,000 warrants), Piyush Jashbhai Patel (5,00,000 warrants), and Sanjay Patel Holdings Private Limited (1,00,000 warrants)\n• Warrants will be subject to lock-in period as per SEBI regulations\n• No immediate change in capital structure until warrants are converted",{"company_name":160,"filing_date":161,"filing_source":9,"headline":162,"id":163,"stock_code":164,"summary_text":165},"Prism Johnson Limited","2025-12-18T10:45:04.501000","Board Approves Sale of Mumbai Office Premises for Rs.165.91 Crores","69438e2f3418e54cdf8e985e","PRSMJOHNSN","• The Board has approved selling office premises at Windsor, 7th Floor, CST Road, Kalina, Mumbai to Windsor Realty Private Limited\n• The transaction value is Rs.165.91 Crores with completion expected by December 31, 2025\n• This is a related party transaction as the buyer has connections to Director Mr. Akshay Raheja",{"company_name":167,"filing_date":168,"filing_source":21,"headline":169,"id":170,"stock_code":171,"summary_text":172},"Prism Johnson Ltd","2025-12-18T10:40:05.345000","Sale of Mumbai Office Premises to Related Party for Rs.165.91 Crores","69438d22a83e03833de03d04","500338","• Board approved sale of office premises at Windsor, 7th Floor, CST Road, Kalina, Mumbai to Windsor Realty Private Limited\n• Transaction value: Rs.165.91 Crores with sale deed to be executed by December 31, 2025\n• Related party transaction: Buyer connected to Director Akshay Raheja and his relative Rajan Raheja",{"company_name":167,"filing_date":168,"filing_source":21,"headline":162,"id":174,"stock_code":171,"summary_text":175},"69438d2333cbfe5de72211c7","• Board approved sale of office premises at Windsor, 7th Floor, CST Road, Kalina, Mumbai to Windsor Realty Private Limited\n• Transaction value: Rs.165.91 Crores, to be completed by December 31, 2025\n• Related party transaction: Buyer connected to Director Mr. Akshay Raheja and his relative Mr. Rajan Raheja",{"company_name":134,"filing_date":177,"filing_source":9,"headline":178,"id":179,"stock_code":138,"summary_text":180},"2025-12-18T10:40:04.777000","Shriram Finance Responds to Media Speculation About MUFG Investment","69438d03ca5c132761217fec","• Company clarifies it has not executed any binding agreement with investors regarding reported $5 billion MUFG stake\n• Board meeting scheduled for December 19, 2025 to consider proposals for raising funds through various avenues\n• Trading window closed for designated persons since December 17, 2025\n• Company cites SEBI circular that exempts them from confirming\u002Fdenying rumors during pre-intimation period before board meeting\n• No undisclosed information that requires disclosure under Regulation 30 of Listing Regulations at this stage",{"company_name":182,"filing_date":183,"filing_source":21,"headline":184,"id":185,"stock_code":186,"summary_text":187},"Alfavision Overseas India Ltd","2025-12-18T10:35:04.180000","Writ Petition Notice Issued by High Court in Land Acquisition Matter","69438b991cc49bc09be03dac","531156","• Company filed Writ Petition 30041\u002F2022 at Indore High Court regarding 9.8 acres of land in Ujjain\n• Petition relates to a letter of intent (No. MPSTC\u002F95\u002FMNG\u002F97\u002FASSETS\u002FITU\u002F1384) from MP Textile Corporation Ltd. dated 28\u002F11\u002F1998\n• Court has issued notice to respondents after hearing on admission question on December 9, 2025\n• Company directed to pay process fee via R.A.D. mode within 7 working days\n• Notices made returnable within 8 weeks\n• Company is taking steps to comply with court directions",{"company_name":189,"filing_date":190,"filing_source":21,"headline":191,"id":192,"stock_code":193,"summary_text":194},"Genesys International Corporation Ltd","2025-12-18T10:30:05.509000","Genesys International Advances India's Mapping Capabilities with New Map Stack","69438ac9ca5c132761217fe3","GENUSPOWER","• Company is building a new India map stack with nationwide constellation of sensors\n• Leveraging team of over 2,000 professionals with specialized mapping expertise\n• Focusing on emerging consumer applications related to mapping technology\n• Positioned to provide cutting-edge solutions for enterprise and government markets\n• Combining advanced mapping capabilities with deep understanding of technology applications",{"company_name":196,"filing_date":197,"filing_source":9,"headline":198,"id":199,"stock_code":200,"summary_text":201},"Genesys International Corporation Limited","2025-12-18T10:25:04.170000","Genesys International Advances India's Mapping Technology with New Map Stack","6943897b09f3f457de8e979d","GENESYS","• Building a comprehensive new India map stack with nationwide constellation of sensors\n• Leveraging team of over 2,000 professionals with specialized mapping expertise\n• Focusing on emerging consumer applications related to mapping technology\n• Developing cutting-edge solutions for enterprise and government markets\n• Positioning as a premier advanced mapping company in India's growing geospatial sector",{"company_name":203,"filing_date":204,"filing_source":21,"headline":205,"id":206,"stock_code":207,"summary_text":208},"Global Longlife Hospital and Research Ltd","2025-12-18T10:20:05.224000","Promoter Sucheta Jani Reduces Stake by 5.67% Through Open Market Sale","694389271cc49bc09be03da1","543520","• Promoter Sucheta Dhruvkumar Jani sold 5,95,000 equity shares (5.67% stake) of the company\n• Transaction conducted via open market between December 12-17, 2025\n• Shareholding reduced from 15,63,000 shares (14.89%) to 9,68,000 shares (9.22%)\n• Total equity capital remains unchanged at Rs. 10,50,00,000 (1,05,00,000 shares of Rs. 10 each)\n• Disclosure filed under SEBI Substantial Acquisition of Shares and Takeovers Regulations",{"company_name":210,"filing_date":211,"filing_source":21,"headline":212,"id":213,"stock_code":214,"summary_text":215},"Asian Paints Ltd","2025-12-18T10:20:05.131000","Promoter Group Disclosure of Share Encumbrances","6943888a33cbfe5de72211ab","500820","* Total promoter group holds 52.63% of Asian Paints shares\n* 5.22% of total shares (5,00,65,727 shares) are encumbered\u002Fpledged\n* Sattva Holding and Trading Private Limited has pledged 77,26,000 shares (0.81%)\n* Several family members and trusts hold small percentages with minimal or no pledges\n* Document signed by Vita J Dani, Managing Director of Smiti Holding and Trading Company Private Limited",{"company_name":217,"filing_date":218,"filing_source":9,"headline":219,"id":220,"stock_code":221,"summary_text":222},"Black Box Limited","2025-12-18T10:20:04.522000","Black Box Converts 71,944 Warrants to Equity Shares in ₹3 Crore Preferential Allotment","694388533418e54cdf8e9840","BBOX","• Company allotted 71,944 equity shares at ₹417 per share (₹2 face value + ₹415 premium)\n• Total consideration received: ₹3,00,00,648 (approximately ₹3 crore)\n• Shares issued to Ushma Mehta (non-promoter) upon conversion of warrants\n• Minimal dilution impact: Allottee's holding increases from 0.30% to 0.34% of total shares\n• Paid-up capital increases from ₹34,05,62,200 to ₹34,07,06,088\n• 71,42,211 warrants remain outstanding for potential future conversion",{"company_name":217,"filing_date":218,"filing_source":9,"headline":224,"id":225,"stock_code":221,"summary_text":226},"Black Box Converts 71,944 Warrants to Equity Shares in Preferential Allotment","694388541cc49bc09be03d9a","• Company allotted 71,944 equity shares (face value Rs. 2\u002F- each) at Rs. 417\u002F- per share (including Rs. 415\u002F- premium)\n• Total consideration received: Rs. 3,00,00,648 (approximately Rs. 3 crore)\n• Shares issued to non-promoter Ushma Mehta upon conversion of warrants\n• Minimal dilution impact: Allottee's shareholding increases from 0.30% to 0.34%\n• Paid-up capital increases from Rs. 34,05,62,200\u002F- to Rs. 34,07,06,088\u002F-\n• 71,42,211 warrants remain outstanding for potential future conversion",{"company_name":228,"filing_date":229,"filing_source":21,"headline":230,"id":231,"stock_code":232,"summary_text":233},"Davin Sons Retail Ltd","2025-12-18T10:15:05.693000","Promoters Acquire Convertible Warrants Through Preferential Allotment","69438720ca5c132761217fcc","544331","* Mohit Arora and Nohit Arora (Promoters) acquired 11,50,000 warrants convertible into equity shares\n* Mohit Arora acquired 6,50,000 warrants (9.83% of total share capital)\n* Nohit Arora acquired 5,00,000 warrants (7.56% of total share capital)\n* Transaction completed via preferential allotment on December 15, 2025\n* After conversion, promoter group's total holding will increase from 63.18% to 67.67%\n* Company also allotted 13,50,000 equity shares to non-promoter category",{"company_name":235,"filing_date":236,"filing_source":9,"headline":237,"id":238,"stock_code":239,"summary_text":240},"Axis Bank Limited","2025-12-18T10:15:04.728000","Malavika R. Harita Appointed as Additional Independent Director","6943874533cbfe5de72211a1","AXISBANK","• Appointed for a four-year term from December 18, 2025 to December 17, 2029\n• Brings 43 years of experience in marketing, communication, and entrepreneurship\n• Former CEO of Saatchi & Saatchi Focus India for 25 years\n• Founder of Brand Circle consultancy firm\n• Serves on multiple boards including IIM Bangalore and Symphony Limited\n• Holds degrees from Bangalore University and IIM Bangalore\n• Appointment strengthens board diversity with marketing and brand strategy expertise",{"company_name":242,"filing_date":243,"filing_source":21,"headline":244,"id":245,"stock_code":246,"summary_text":247},"AXIS Bank Ltd","2025-12-18T10:15:04.374000","Axis Bank Appoints Marketing Veteran Malavika R. Harita as Additional Independent Director","694387271cc49bc09be03d90","532215","• Malavika R. Harita appointed as Additional Independent Director for a four-year term (Dec 18, 2025 to Dec 17, 2029)\n• She brings 43 years of experience in marketing, communication, and entrepreneurship\n• Former CEO of Saatchi & Saatchi Focus in India for 25 years and founder of Brand Circle\n• Currently serves on boards including IIM Bangalore, IIM Visakhapatnam, and Symphony Limited\n• Appointment strengthens the bank's board with expertise in marketing, brand strategy, and entrepreneurship\n• Not related to any Directors or Key Managerial Personnel of the Bank",{"company_name":242,"filing_date":243,"filing_source":21,"headline":249,"id":250,"stock_code":246,"summary_text":251},"Appointment of Malavika R. Harita as Additional Independent Director","69438727ca5c132761217fce","• Malavika R. Harita appointed for a four-year term from December 18, 2025 to December 17, 2029\n• She brings 43 years of experience in marketing, communication, and entrepreneurship\n• Former CEO of Saatchi & Saatchi Focus in India for 25 years and founder of Brand Circle\n• Holds board positions at IIM Bangalore, IIM Visakhapatnam, and Symphony Limited\n• Her marketing expertise could strengthen Axis Bank's brand strategy and customer engagement initiatives",{"company_name":253,"filing_date":254,"filing_source":9,"headline":255,"id":256,"stock_code":257,"summary_text":258},"Aurobindo Pharma Limited","2025-12-18T10:10:04.279000","US FDA Issues Form 483 with 5 Observations After Inspection of APL Healthcare Unit-IV","694386191cc49bc09be03d8b","AUROPHARMA","• US FDA conducted inspection of Unit-IV of APL Healthcare Limited (wholly owned subsidiary) in Andhra Pradesh from December 8-17, 2025\n• FDA issued Form 483 with 5 observations which are procedural in nature\n• Company will respond to the FDA within stipulated timelines\n• Management confirms no impact on financials or operations of the facility\n• Company reaffirms commitment to maintaining high quality manufacturing standards",{"company_name":253,"filing_date":254,"filing_source":9,"headline":260,"id":261,"stock_code":257,"summary_text":262},"US FDA Issues Form 483 with 5 Observations Following Inspection at APL Healthcare Unit-IV","6943861909f3f457de8e9795","• US FDA conducted inspection at Unit-IV of APL Healthcare Limited (wholly owned subsidiary) in Andhra Pradesh from December 8-17, 2025\n• FDA issued Form 483 with 5 procedural observations at the conclusion of inspection\n• Company will respond to the FDA within stipulated timelines\n• Management confirms no financial or operational impact on the facility\n• Company reaffirms commitment to maintaining high quality manufacturing standards across all facilities",{"company_name":264,"filing_date":265,"filing_source":21,"headline":266,"id":267,"stock_code":257,"summary_text":268},"Aurobindo Pharma Ltd","2025-12-18T10:10:03.950000","US FDA Inspection Completed at APL Healthcare Unit-IV with Form 483 Observations","694385faca5c132761217fc4","• US FDA inspected Unit-IV of APL Healthcare Limited (wholly owned subsidiary) in Andhra Pradesh from December 8-17, 2025\n• FDA issued Form 483 with 5 procedural observations which the company will respond to within stipulated timelines\n• Company states these observations will not impact financial operations of the facility\n• Aurobindo remains committed to maintaining highest quality manufacturing standards across all facilities",{"company_name":270,"filing_date":271,"filing_source":9,"headline":272,"id":273,"stock_code":274,"summary_text":275},"NIBE Limited","2025-12-18T10:05:04.692000","NIBE Limited Announces Board Meeting for Preferential Issue Fundraising","694384ab33cbfe5de7221191","NIBE","• NIBE Limited has scheduled a board meeting on December 23, 2025 to discuss fundraising via preferential issue\n• Trading window will remain closed from December 15 to December 25, 2025\n• The specific amount, instrument type (equity\u002Fdebt\u002Fconvertible), and purpose of the fundraising are not disclosed in the filing\n• Potential implications include changes to capital structure and dilution for existing shareholders if equity is issued\n• This fundraising initiative likely signals company plans for growth, expansion, or debt restructuring",{"company_name":277,"filing_date":278,"filing_source":9,"headline":279,"id":280,"stock_code":281,"summary_text":282},"Cyber Media Research & Services Limited","2025-12-18T10:05:04.560000","Q2FY25-26 Earnings Call Transcript Now Available","694384cdca5c132761217fbf","CMRSL","• Transcript of the December 11, 2025 investor conference call discussing Q2FY25-26 results has been released\n• The 56-minute call featured presentations and Q&A with management, including Managing Director Mr. Dhaval Gupta\n• Document was filed in compliance with SEBI Listing Obligations and Disclosure Requirements\n• Transcript is now accessible on the company website at www.cmrsl.net",{"company_name":277,"filing_date":278,"filing_source":9,"headline":284,"id":285,"stock_code":281,"summary_text":286},"Q2FY26 Earnings Call Transcript Now Available","694384cf1cc49bc09be03d84","• Transcript of the December 11, 2025 investor conference call discussing Q2FY26 results is now available\n• The call featured presentations from the company's Managing Director, Mr. Dhaval Gupta\n• Investors can access the complete transcript on the company's website at www.cmrsl.net\n• The filing was submitted to comply with SEBI Listing Obligations and Disclosure Requirements",{"company_name":288,"filing_date":289,"filing_source":21,"headline":290,"id":291,"stock_code":292,"summary_text":293},"Ind-Swift Laboratories Ltd","2025-12-18T09:55:05.002000","Promoter Shareholding Update: Transmission of 2,32,057 Shares to Legal Heirs","69438258ca5c132761217fb6","INDSWFTLAB","• 2,32,057 equity shares of Late Mrs. Neera Mehta have been transmitted to the joint demat account of her three legal heirs\n• The legal heirs are Mr. Rishav Mehta, Ms. Ishav Mehta, and Mr. Daksh Mehta\n• The transmission was completed on December 17, 2025, following regulatory approvals\n• This transfer falls under exemption provided in Regulation 10(1)(g) of SEBI SAST Regulations\n• There is no change in the aggregate shareholding of the Promoters and Promoter Group\n• The shares were previously pending credit due to regulatory approvals related to the amalgamation of Ind-Swift Limited with Ind-Swift Laboratories Limited",{"company_name":295,"filing_date":296,"filing_source":21,"headline":297,"id":298,"stock_code":299,"summary_text":300},"Nucleus Software Exports Ltd","2025-12-18T09:55:04.198000","Nucleus Software Unveils AI-Defined Banking Blueprint and Releases FinnOne Neo GA 8.5","69438275ed00186c83217f1f","NUCLEUS","• Launched FinnOne Neo GA 8.5, a significant update to their flagship banking software platform\n• Introduced an AI-Defined Banking Blueprint for the Indian market at Synapse 2025 event\n• Strategic positioning as an AI-driven solution provider for the banking sector\n• Enhances market competitiveness by integrating advanced AI capabilities into core banking products\n• Demonstrates commitment to innovation in financial technology for the Indian market\n• Likely to strengthen revenue streams through new feature adoption and potential client acquisition",{"company_name":302,"filing_date":303,"filing_source":21,"headline":304,"id":305,"stock_code":306,"summary_text":307},"Grameva Ltd","2025-12-18T09:45:04.390000","Jagsakti Merchandise Private Limited Reduces Stake in Bangalore Fort Farms","6943801f33cbfe5de7221185","539120","* Bhanu Mahajan, Director of Jagsakti Merchandise Private Limited, has sold 222,812 shares (4.64% stake)\n* Transaction executed via off-market sale between October 17-25, 2025\n* Shareholding reduced from 795,000 shares (16.56%) to 572,188 shares (11.92%)\n* Transaction disclosed in SEBI filing dated December 17, 2025\n* Seller is not part of the promoter\u002Fpromoter group\n* Shares are listed on both BSE and Calcutta Stock Exchange",{"company_name":302,"filing_date":303,"filing_source":21,"headline":309,"id":310,"stock_code":306,"summary_text":311},"Jagsakti Merchandise Reduces Stake in Bangalore Fort Farms by 4.64%","69438020ca5c132761217fb0","• Bhanu Mahajan, Director of Jagsakti Merchandise Private Limited, has sold 222,812 shares (4.64% stake)\n• Transaction executed via off-market sale between October 17-25, 2025\n• Shareholding reduced from 795,000 shares (16.56%) to 572,188 shares (11.92%)\n• The seller is not part of the promoter\u002Fpromoter group\n• Total equity share capital remains unchanged at 4,799,400 shares\n• Filing disclosed under SEBI Regulation 29(2) for substantial shareholding changes",{"company_name":313,"filing_date":314,"filing_source":21,"headline":315,"id":316,"stock_code":317,"summary_text":318},"Balurghat Technologies Ltd","2025-12-18T09:40:03.882000","Promoter Pawan Kumar Sethia Acquires Additional Shares in Balurghat Technologies","69437eb4a471cc3842221101","520127","• Promoter Pawan Kumar Sethia and Pawan Kumar Sethia HUF acquired 650 additional shares\n• Transaction executed online on December 16, 2025\n• Shareholding increased from 26,850 shares (0.15%) to 27,500 shares (0.15%)\n• Total equity share capital remains 1,82,00,000 shares of Rs. 10\u002F- each\n• Disclosure filed under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations",{"company_name":320,"filing_date":321,"filing_source":21,"headline":322,"id":323,"stock_code":324,"summary_text":325},"Apollo Micro Systems Ltd","2025-12-18T09:30:04.489000","Investor Presentation for Q2FY2026 Available for Analyst\u002FInstitutional Investor Meet","69437c9b3418e54cdf8e9815","APOLLO","• Company confirms no new presentation will be created for upcoming investor meetings\n• Existing Q2FY2026 investor presentation will be used for analyst\u002Finstitutional investor interactions\n• Presentation is available on company website via provided link: https:\u002F\u002Fapollo-micro.in\u002Fapi\u002Ffiles\u002Freports\u002Fa7031b20-0937-4a6a-8ebb-fb66d51f21ef-4.-investor-presentation-for-the-quarter-and-half-year-ended-30th-september,-2025.pdf",{"company_name":320,"filing_date":321,"filing_source":21,"headline":327,"id":328,"stock_code":324,"summary_text":329},"Q2FY2026 Investor Presentation Available for Analyst\u002FInstitutional Investor Meet","69437c9b33cbfe5de722117d","• Company confirms no new presentation will be created for upcoming investor meetings\n• Existing Q2FY2026 presentation will be used for analyst\u002Finstitutional investor interactions\n• Presentation is available on company website via direct link: https:\u002F\u002Fapollo-micro.in\u002Fapi\u002Ffiles\u002Freports\u002Fa7031b20-0937-4a6a-8ebbfb66d51f21ef-4.-investor-presentation-for-the-quarter-and-half-year-ended-30th-september,-2025.pdf",{"company_name":331,"filing_date":332,"filing_source":9,"headline":333,"id":334,"stock_code":335,"summary_text":336},"Mtar Technologies Limited","2025-12-18T09:25:04.166000","Major Order Win in Civil Nuclear Power Sector","69437b2d3418e54cdf8e9811","MTARTECH","• Secured orders worth ₹310 crores from Megha Engineering & Infrastructures Ltd\n• Orders for various equipment for Kaiga 5 and 6 civil nuclear reactors\n• First major order from a new customer in the Civil Nuclear Power sector\n• Delivery schedule extends through February 2030 with staggered deliveries\n• Order represents significant expansion in MTAR's nuclear power portfolio",{"company_name":331,"filing_date":338,"filing_source":9,"headline":339,"id":340,"stock_code":335,"summary_text":341},"2025-12-18T09:20:04.054000","MTAR Secures Rs. 310 Crores in Nuclear Power Orders","69437a433418e54cdf8e980e","• Company has received orders worth Rs. 310 Crores for Kaiga 5 & 6 reactors in Civil Nuclear Power Sector\n• Total orders for Kaiga 5 & 6 reactors now aggregate to Rs. 504 Crores this month, including an earlier order of Rs. 194 Crores\n• Management expects strong growth in the nuclear segment, supported by robust order book\n• No related party transactions or promoter interests involved in these orders\n• Reinforces MTAR's established position in the Civil Nuclear Power sector, where it has decades-long relationships",{"company_name":331,"filing_date":338,"filing_source":9,"headline":343,"id":344,"stock_code":335,"summary_text":345},"MTAR Secures Rs. 310 Crores Orders for Kaiga Nuclear Reactors","69437a44a83e03833de03cf7","• MTAR has received new orders worth Rs. 310 Crores for Kaiga 5 & 6 reactors in the Civil Nuclear Power Sector\n• Total orders for Kaiga 5 & 6 now aggregate to Rs. 504 Crores this month, including an earlier order of Rs. 194 Crores\n• Management expects strong growth in the nuclear segment, supported by robust order book and favorable industry outlook\n• The company has strategic manufacturing capabilities across clean energy, space and defense sectors\n• MTAR maintains long-standing relationships with leading Indian organizations and global OEMs",{"company_name":347,"filing_date":348,"filing_source":9,"headline":349,"id":350,"stock_code":351,"summary_text":352},"Sun Pharmaceutical Industries Limited","2025-12-18T08:30:05.446000","US FDA determines Sun Pharma's Baska facility inspection classification as OAI","69436e6aa83e03833de03cf5","SUNPHARMA","• US FDA conducted an inspection at Sun Pharma's Baska facility from September 8-19, 2025\n• The facility has been classified as \"Official Action Indicated\" (OAI) by the US FDA\n• Sun Pharma continues to manufacture and supply approved products from this facility to the US market\n• The company will work with the regulator to achieve fully compliant status",{"company_name":354,"filing_date":355,"filing_source":21,"headline":356,"id":357,"stock_code":351,"summary_text":358},"Sun Pharmaceutical Industries Ltd","2025-12-18T08:30:04.354000","US FDA determines Baska facility inspection classification as OAI","69436e491cc49bc09be03d59","• US FDA conducted an inspection at Sun Pharma's Baska facility from September 8-19, 2025\n• The facility has been classified as \"Official Action Indicated\" (OAI) by the US FDA\n• Company will continue to manufacture and supply approved products from this facility to the US market\n• Sun Pharma is working with the regulator to achieve fully compliant status",{"company_name":360,"filing_date":361,"filing_source":21,"headline":362,"id":363,"stock_code":364,"summary_text":365},"ACME Solar Holdings Ltd","2025-12-18T08:25:03.828000","ACME Solar secures INR 4,725 crore debt financing to fund renewable energy projects","69436d5c33cbfe5de7221164","ACMESOLAR","* Secured INR 4,725 crore debt financing from leading Indian financial institutions\n* New greenfield financing: INR 2,716 crore from PFC Ltd for 300 MW ACME Sigma FDRE project with battery storage\n* Additional INR 800 crore from NaBFID for 150 MW ACME Platinum Solar + ESS project\n* Refinancing: INR 1,209 crore from Yes Bank for operational 300 MW ACME Sikar Solar project, reducing debt cost by 170-195 bps\n* Total debt secured in current fiscal year: ~INR 10,590 crore (90% of PPA signed under-construction projects)\n* Refinanced ~INR 3,380 crore debt with ~135 bps rate reduction\n* Expanded non-fund based limits from various banks including ICICI, Standard Chartered, First Abu Dhabi Bank, EXIM Bank",{"company_name":360,"filing_date":361,"filing_source":21,"headline":367,"id":368,"stock_code":364,"summary_text":369},"ACME Solar Secures INR 4,725 Crore Debt Financing for Renewable Projects","69436d5cca5c132761217f8e","* Secured INR 4,725 crore debt financing from leading Indian financial institutions\n* New greenfield financing: INR 2,716 crore from PFC Ltd for 300 MW ACME Sigma FDRE project\n* First greenfield financing from NaBFID: INR 800 crore for 150 MW ACME Platinum Solar + ESS project\n* Refinancing: INR 1,209 crore from Yes Bank for operational 300 MW ACME Sikar Solar project\n* Achieved cost reduction of 170-195 bps through refinancing\n* Expanded non-fund based limits from various banks including ICICI, Standard Chartered, First Abu Dhabi Bank, and EXIM Bank\n* Total renewable portfolio now stands at 7,520 MW (2,942 MW operational, 4,578 MW under construction)",{"company_name":371,"filing_date":372,"filing_source":21,"headline":373,"id":374,"stock_code":375,"summary_text":376},"Indian Overseas Bank","2025-12-18T08:20:04.436000","Government of India to Divest 2.395% Stake in Indian Overseas Bank Through Offer for Sale","69436c3a3418e54cdf8e97f6","IOB","• Government of India (promoter) to sell 46,12,25,993 equity shares representing 2.395% of total paid-up equity capital\n• Includes base offer of 38,51,31,796 shares (2%) plus oversubscription option of 7,60,94,197 shares (0.395%)\n• 4,61,22,600 shares (10% of offer) reserved for retail investors on December 18, 2025\n• 1,50,000 shares (0.001% of capital) allocated to employees\n• Shares have face value of ₹10 each and will be sold through stock exchange mechanism",{"company_name":371,"filing_date":372,"filing_source":21,"headline":373,"id":378,"stock_code":375,"summary_text":379},"69436c3aca5c132761217f8a","• Government of India (promoter) to sell 46,12,25,993 equity shares representing 2.395% of total paid-up equity capital\n• Base offer size of 38,51,31,796 shares (2%) with partial exercise of oversubscription option for additional 7,60,94,197 shares (0.395%)\n• 4,61,22,600 shares (10% of offer) reserved for retail investors on December 18, 2025\n• 1,50,000 shares (0.001% of capital) allocated for employees\n• Shares have face value of ₹10 each and will be sold through stock exchange mechanism",{"company_name":381,"filing_date":382,"filing_source":9,"headline":383,"id":384,"stock_code":385,"summary_text":386},"Cholamandalam Investment and Finance Company Limited","2025-12-18T07:25:03.848000","Allotment of 98,980 Equity Shares Under ESOP","69435f0c1cc49bc09be03d43","CHOLAFIN","• The company has allotted 98,980 equity shares following exercise of Employee Stock Options\n• Paid-up share capital increased from ₹1,687,706,982 to ₹1,687,904,942\n• Total number of outstanding shares increased from 843,853,491 to 843,952,471\n• This represents a minimal dilution of approximately 0.012% to existing shareholders\n• The ESOP allotment was approved by the Board on October 27, 2016",{"company_name":388,"filing_date":389,"filing_source":21,"headline":390,"id":391,"stock_code":385,"summary_text":392},"Cholamandalam Investment and Finance Company Ltd","2025-12-18T07:15:04.579000","Employee Stock Options Exercised: 98,980 Equity Shares Allotted","69435cf7a471cc38422210fd","• The Nomination and Remuneration Committee has approved allotment of 98,980 equity shares\n• Each share is valued at Rs.2\u002F- face value\n• Shares were allotted to employees who exercised options under the ESOP scheme\n• Company will apply for final listing of these shares on NSE and BSE",{"company_name":388,"filing_date":389,"filing_source":21,"headline":394,"id":395,"stock_code":385,"summary_text":396},"Allotment of 98,980 Equity Shares Under Employee Stock Option Scheme","69435cf7ca5c132761217f70","• Company has approved allotment of 98,980 equity shares of Rs.2\u002F- each\n• Shares issued to employees who exercised options under the ESOP scheme\n• Company will apply for final listing of these shares on NSE and BSE\n• This is not a dividend, split, bonus, rights issue or buyback\n• Minimal dilution impact for existing shareholders due to small issuance size",{"company_name":398,"filing_date":399,"filing_source":9,"headline":400,"id":401,"stock_code":402,"summary_text":403},"Zota Health Care LImited","2025-12-18T01:09:05.416000","Zota Health Care Raises ₹350 Crore Through QIP, Issues 22.8 Lakh Equity Shares","694306f3439666579011068e","ZOTA","• Company successfully completed a Qualified Institutions Placement (QIP) raising ₹349.99 crore\n• Issued 22,80,130 equity shares at ₹1,535 per share (including premium of ₹1,525)\n• Paid-up equity capital increased from ₹30.89 crore to ₹33.17 crore\n• Share capital dilution of approximately 7.4% (new shares represent 6.9% of expanded capital)\n• Major investors include Valiant Mauritius Partners entities (42.86%), Ashoka Whiteoak (11.65%)\n• Capital structure strengthened to support company's growth initiatives\n• QIP closed on December 17, 2025 with allotment approved the same day",false,100,7,667]